Загрузка...
Update on use of aldesleukin for treatment of high-risk metastatic melanoma
High-dose interleukin-2 has been used for the treatment of metastatic melanoma since 1998 based on data proving durable complete responses in up to 10% of treated patients. The immunomodulatory effects of this critical cytokine have been instrumental in the development of immunotherapy for melanoma...
Сохранить в:
| Опубликовано в: : | Immunotargets Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918260/ https://ncbi.nlm.nih.gov/pubmed/27471714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S61590 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|